Two PARP inhibitors, namely olaparib and talazoparib, have been approved as monotherapies for the management of locally advanced/metastatic HER2-negative BC, in patients with BRCA1 or 2 germline mutations [6,22,23,27]. This evidence concerns the gene ERBB2 and breast cancer.